Project Grant 1256477

This Cooperative Agreement award from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program provides $1,250,000 in funding to Biodevek Inc., a Boston-based small business, to advance the development of a novel hydrogel delivery system for managing gastrointestinal (GI) lesions and bleeding. The project aims to create the first sprayable hemostatic hydrogel solution for endoscopic procedures, with the potential to improve outcomes, reduce...

Karios Technologies LLC, a for-profit organization, received a $274,954 SBIR Phase I grant from the National Science Foundation (NSF) Technology, Innovation, and Partnerships program (CFDA 47.084) to develop a novel, ready-to-use, large volume delivery system for in situ forming biomaterials. The biomaterials are intended to serve as tissue sealants, scar tissue reducers, and vehicles for drug or cell delivery during surgical procedures. The project aims to transfer a proprietary biomaterial...

This $999,783 Phase II Small Business Innovation Research (SBIR) cooperative agreement from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program supports Intact Therapeutics' development of a thermogel-based drug delivery platform for the treatment of upper gastrointestinal bleeding (UGIB). Intact Therapeutics' proprietary thermogel technology aims to rapidly stop UGIB prior to endoscopic treatment, potentially reducing patient morbidity,...

Federal Project Grant Award Summary Limax Biosciences Inc. received a $464,229 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate HEMOMAX, a biodegradable hydrogel adhesive sealant for vascular surgery. The award, obligated on August 20, 2025, with completion targeted for July 31, 2026, supports a Phase I effort to advance the product toward FDA approval and commercial viability. The...

The U.S. Department of Defense (DoD) Defense Health Agency awarded a $1,820,004 Project Grant to Case Western Reserve University's Office of Research Administration Division, doing business as the University Hospitals of Cleveland, under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "HEMOSEAL: COMBINATORIAL NANOPARTICLE TECHNOLOGY FOR POINT-OF-INJURY HEMORRHAGE CONTROL," will support the development of an innovative nanoparticle-based technology...

The U.S. Department of Defense's Defense Health Agency has awarded a $902,109 Project Grant to North Carolina State University (NC State) under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "HEMOSEAL: COMBINATORIAL NANOPARTICLE TECHNOLOGY FOR POINT-OF-INJURY HEMORRHAGE CONTROL," supports the development of advanced nanoparticle-based technologies to improve hemorrhage control at the point of injury. The award period runs from July 1, 2024 to...

The Texas A&M Engineering Experiment Station (Tees) was awarded a $2,404,778 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will support research and development of expandable hemostats for treatment of noncompressible intracaivitary hemorrhage from August 15, 2022 to August 14, 2026. Through this funding, Tees will investigate medical solutions for uncontrolled bleeding on the battlefield,...

The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $350,000 Project Grant to Karios Technologies LLC to develop TissueShield, a novel single-use, ready-to-use, sterile, dual-chamber, dual-syringe sprayable hydrogel for preventing post-surgical cardiac adhesions. TissueShield is a 3-component polymer system that can be easily sprayed directly onto the heart, forming a robust anti-adhesion layer within seconds. The...

The Department of the Army Medical Command awarded Cayuga Biotech Inc. a $922,870 Project Grant under the Military Medical Research and Development program (CFDA 12.420). The grant will support Cayuga Biotech's development of an intravenous agent for traumatic hemorrhage control from July 1, 2021 to June 30, 2022. The Military Medical Research and Development program aims to transform military and public health through innovative medical research solutions, including investigations into...

Case Western Reserve University will receive $2,469,361 from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program to support the SANGUISTOP project. This four-year Project Grant will fund research into intravenous nanomedicine for targeted thrombin delivery in hemorrhage control. The Military Medical Research and Development program aims to transform military and public health care through innovative medical solutions for...